Skip to main content

Table 2 Association factors of OS and DFS in the total patients

From: Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study

 

Overall survival

Disease-free survival

Univariable analysis

Multivariable analysis

Univariable analysis

Multivariable analysis

Factors

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

Treatment

 Surgery alone

1 (Reference)

–

  

1 (Reference)

–

1 (Reference)

–

 Surgery/adjuvant chemotherapy

0.733 (0.486–1.106)

0.139

  

0.673 (0.447–1.012)

0.057

0.511 (0.322–0.811)

0.004

Age of diagnosis

 65–70 years

1 (Reference)

–

1 (Reference)

–

1 (Reference)

–

  

  > 70 years

1.560 (1.021–2.385)

0.028

1.640 (1.119–2.403)

0.011

1.422 (0.978–2.067)

0.065

  

Time of surgery

 2004–2014

1 (Reference)

–

  

1 (Reference)

–

1 (Reference)

–

 2015–2018

0.967 (0.632–1.478)

0.876

  

0.713 (0.475–1.069)

0.102

0.586 (0.376–0.912)

0.018

Sex

 Male

1 (Reference)

–

  

1 (Reference)

–

  

 Female

0.903 (0.589–1.383)

0.638

  

0.895 (0.588–1.361)

0.603

  

ECOG score

 0

1 (Reference)

–

  

1 (Reference)

–

  

 1

1.325 (0.879–1.996)

0.179

  

1.468 (0.982–2.194)

0.062

  

 2

1.006 (0.504–2.008)

0.987

  

1.105 (0.554–2.202)

0.777

  

 2+

2.016 (0.797–5.100)

0.139

  

2.017 (0.798–5.097)

0.138

  

Charlson score

 0

1 (Reference)

–

  

1 (Reference)

–

  

 1

1.029 (0.631–1.679)

0.909

  

1.068 (0.661–1.724)

0.788

  

 2

0.992 (0.363–2.710)

0.988

  

1.182 (0.479–2.961)

0.716

  

 2+

1.135 (0.158–8.174)

0.900

  

1.368 (0.190–9.852)

0.756

  

Tumor location

 Gastroesophageal junction

1 (Reference)

–

  

1 (Reference)

–

  

 Antrum

1.304 (0.841–2.023)

0.236

  

1.321 (0.861–2.027)

0.203

  

 Other

1.511 (0.832–2.724)

0.175

  

1.497 (0.840–2.670)

0.171

  

Retrieved lymph node

1.002 (0.9931.011)

0.656

  

0.999 (0.990–1.008)

0.841

  

Hospital stays

1.003 (0.983–1.023)

0.793

  

1.006 (0.987–1.025)

0.550

  

AJCC stage

 II

1 (Reference)

–

1 (Reference)

–

1 (Reference)

–

1 (Reference)

–

 III

2.626 (1.610–4.284)

< 0.001

2.738 (1.677–4.471)

< 0.001

2.345 (1.466–3.751)

< 0.001

2.345 (1.466–3.751)

< 0.001

Histologic Grade

 Well or moderately differentiated

1 (Reference)

–

  

1 (Reference)

–

  

 Poorly differentiated or undifferentiated

1.293 (0.809–2.068)

0.283

  

1.247 (0.788–1.975)

0.346

  

Lymphatic, blood vessel or perineural invasion

 Yes

1 (Reference)

–

  

1 (Reference)

–

  

 No

0.857 (0.581–1.7266

0.439

  

0.740 (0.505–1.083)

0.121

  

Tumor size

  ≤ 5 cm

1 (Reference)

–

1 (Reference)

 

1 (Reference)

–

  

  > 5 cm

1.610 (1.099–2.356)

0.014

1.356 (0.921–1.996)

0.123

1.440 (0.991–2.091)

0.560

  

CTC

0.937 (0.802–1.096)

0.416

  

1.007 (0.924–1.088)

0.866

  
  1. HR hazards ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, AJCC American Joint Cancer Committee, CTC circulating tumor cells
  2. We adjusted for the following variables: treatment regimens (with adjuvant chemotherapy or not), age of diagnosis, time of surgery, sex, ECOG score, Charlson score, tumor location, retrieved lymph node, hospital stays, AJCC stage, histologic grade, lymphatic, blood vessel or perineural invasion, tumor size, and CTC counts
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us